{"product_id":"supernus-swot-analysis","title":"Supernus Pharmaceuticals SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrengthen Investment Review with the Full SWOT Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals has clear strengths in its focused CNS portfolio and commercial capabilities, but it also faces portfolio concentration, R\u0026amp;D reliance, patent risk, and pricing pressure; future performance will depend on pipeline execution and operating discipline. Review the full SWOT analysis for a deeper view of financial context, competitive positioning, risk scenarios, and decision-making insights relevant to investors. Purchase the complete report-Word and Excel deliverables included-to support informed analysis and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust ADHD Market Presence with Qelbree\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpqelbree has become a central pillar of supernus pharmaceuticals growth in adhd driving revenue where qelbree sales reached million ytd through q3 up year-over-year. its non-stimulant non-controlled profile offers competitive alternative to stimulants that face abuse and periodic shortages reducing prescribing friction for clinicians. by end-2025 secured roughly share pediatric adult prescriptions the us solidifying companys base.\u003e\n\u003c\/pqelbree\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpertise in CNS Drug Delivery Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSupernus leverages proprietary MicroFusion and SoluMatrix platforms to boost CNS drug bioavailability and enable controlled release, improving adherence-benefiting products like Trokendi XR where extended-release formulations drove $138M in 2024 U.S. net sales. These technologies raise technical barriers to entry and cut development timelines; SoluMatrix particles achieve submicron sizes that can increase dissolution rates by \u0026gt;40%, supporting next-gen CNS assets in clinical pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Commercial Footprint in Neurology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus maintains a 120-person specialty sales force focused on neurologists and psychiatrists, yielding above-industry detailing rates and helping sustain Net Product Sales of $585 million in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Product Portfolio across CNS Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSupernus's portfolio covers epilepsy, ADHD and movement disorders, lowering risk if one area falls; neurology sales were $356m in 2024 with epilepsy\/ADHD core contributors.\u003c\/p\u003e\n\u003cp\u003eOxtellar XR and GOCOVRI (approved 2017) plus newer ADHD launches create layered revenue, with GOCOVRI net sales ~$102m in 2024 and ADHD product growth of ~18% YoY.\u003c\/p\u003e\n\u003cp\u003eThe breadth lets Supernus target multiple unmet needs across neurology, supporting steady cash flow and R\u0026amp;D leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNeurology sales $356m (2024)\u003c\/li\u003e\n\u003cli\u003eGOCOVRI sales ~$102m (2024)\u003c\/li\u003e\n\u003cli\u003eADHD portfolio growth ~18% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSolid Balance Sheet and Operational Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDespite patent cliffs, Supernus Pharmaceuticals maintained $420 million cash and equivalents at 2024 year-end, supporting R\u0026amp;D spend of $138 million in 2024 to advance CNS pipeline and lifecycle programs.\u003c\/p\u003e\n\u003cp\u003eStrong gross margins from legacy products-~72% in 2024-have historically funded strategic pivots and acquisitions, enabling targeted external licensing and M\u0026amp;A.\u003c\/p\u003e\n\u003cp\u003eThis balance-sheet strength lets the company invest in internal innovation and pursue BD deals without immediate dilution or heavy debt.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash: $420M (FY2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D: $138M (FY2024)\u003c\/li\u003e\n\u003cli\u003eGross margin: ~72% (FY2024)\u003c\/li\u003e\n\u003cli\u003eLow leverage: debt\/EBITDA \u0026lt;1x (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQelbree Fuels 2025 Growth: $430M YTD, Strong Neurology Franchise \u0026amp; 72% Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpqelbree drove growth with ytd through q3 yoy and pediatric adult us adhd share microfusion techs raised bioavailability\u003e40% faster dissolution) and supported Trokendi XR ($138M 2024). Strong specialty sales force, diversified neurology portfolio (neurology $356M; GOCOVRI $102M; ADHD +18% YoY), cash $420M, R\u0026amp;D $138M, gross margin ~72% (2024).\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQelbree 2025 YTD (Q3)\u003c\/td\u003e\n\u003ctd\u003e$430M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurology sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$356M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGOCOVRI (2024)\u003c\/td\u003e\n\u003ctd\u003e$102M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$138M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (2024)\u003c\/td\u003e\n\u003ctd\u003e~72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pqelbree\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Supernus Pharmaceuticals, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise SWOT matrix tailored to Supernus Pharmaceuticals, enabling quick strategic alignment and clear communication of R\u0026amp;D strengths, pipeline risks, market opportunities, and regulatory threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Revenue Erosion from Trokendi XR Generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2023 loss of exclusivity for Trokendi XR drove Supernus Pharmaceuticals' legacy epilepsy revenue down sharply, with net product sales falling from $408m in 2021 to $158m in 2024, a ~61% decline. Newer brands (Ogluo, Xadago) must grow by ~\\$250m+ annually to restore pre-generic top-line levels, so investor focus stays on pipeline commercialization and margin recovery. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Setbacks for Late-Stage Pipeline Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRepeated FDA delays for the apomorphine infusion pump SPN-830 have stalled Supernus' Parkinson's expansion, pushing expected product launch beyond 2026 and deferring roughly $120-180m in peak annual revenue previously modeled for 2025-2027; development costs have risen by an estimated $40-60m due to extended trials and resubmissions, and ongoing regulatory hurdles increase time-to-market risk across late-stage assets and strain cash runway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Geographic Concentration in the United States\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals earned about 92% of net product revenue from the United States in 2024, concentrating sales risk domestically and limiting global growth channels.\u003c\/p\u003e\n\u003cp\u003eThis dependence makes Supernus vulnerable to US policy shifts-Medicare pricing reforms or Medicaid rebates could cut margins quickly given limited international offsets.\u003c\/p\u003e\n\u003cp\u003eInternational expansion remains largely unrealized; entering EU or APAC markets would need clinical, regulatory, and commercialization spend likely in the tens of millions to scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarrow Focus on CNS Limiting Therapeutic Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe companys heavy concentration in central nervous system (CNS) therapies leaves it exposed to sector-specific regulatory shifts and trial failures; over 90% of Supernus Pharmaceuticals revenue in 2024 came from CNS products, amplifying downside risk.\u003c\/p\u003e\n\u003cp\u003eUnlike large peers with oncology or immunology units, Supernus lacks diversification to offset CNS headwinds-any major change in CNS treatment guidelines could cut peak sales and valuation sharply.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: if a CNS regimen change trimmed revenues by 25%, 2024 pro forma revenue of roughly $800 million would fall by about $200 million, pressuring margins and stock value.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue ~ $800M; \u0026gt;90% from CNS\u003c\/li\u003e\n\u003cli\u003eNo oncology\/immunology business\u003c\/li\u003e\n\u003cli\u003e25% CNS revenue shock ≈ $200M impact\u003c\/li\u003e\n\u003cli\u003eHigh correlation between CNS outcomes and market cap\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Manufacturers for Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRelying on third-party manufacturers for complex formulations exposes Supernus Pharmaceuticals to supply-chain risk; in 2024 the firm reported 48% of finished-goods volume coming from contract manufacturers, so a single-site disruption could hit revenue quickly.\u003c\/p\u003e\n\u003cp\u003eAny stoppage at a partner site can cause product shortages and market-share loss-on-time delivery slipped to 92.1% in FY2024 for outsourced lines, increasing commercial risk.\u003c\/p\u003e\n\u003cp\u003eMaintaining strict quality control over external facilities is costly and remains an operational vulnerability, with regulatory inspection findings at contract sites rising 14% industry-wide in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e48% of finished goods outsourced (2024)\u003c\/li\u003e\n\u003cli\u003eOn-time delivery 92.1% for outsourced lines (FY2024)\u003c\/li\u003e\n\u003cli\u003eIndustry contract-site inspection findings +14% (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue hit: legacy Trokendi XR slump, SPN‑830 delays force $250M+ replacement gap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy Trokendi XR losses cut product sales ~61% (2021 $408M → 2024 $158M); newer brands must add ~$250M+ annually to restore revenue. FDA delays on SPN-830 pushed launch past 2026, deferring $120-180M peak sales and adding $40-60M development cost. 2024 revenue ≈ $800M with \u0026gt;90% CNS concentration and 48% finished-goods outsourced, raising single-site and US-policy exposure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Estimate\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$800M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrokendi XR sales\u003c\/td\u003e\n\u003ctd\u003e$158M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced volume\u003c\/td\u003e\n\u003ctd\u003e48%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPN-830 deferred peak\u003c\/td\u003e\n\u003ctd\u003e$120-180M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSPN-830 extra cost\u003c\/td\u003e\n\u003ctd\u003e$40-60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eSupernus Pharmaceuticals SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is the real, editable analysis file. Buy now to unlock the complete, detailed Supernus Pharmaceuticals SWOT report immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Expansion for SPN-830 in Parkinson's Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe potential commercialization of SPN-830 could drive significant revenue growth for Supernus Pharmaceuticals; analysts estimate the Parkinson's device-led therapy market may reach $3.2B by 2028, and targeting off episodes could capture a high-value niche with per-patient annual revenues of $8k-$15k.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Advancement of SPN-820 for Depression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSPN-820 targets the mTOR pathway for major depressive disorder, a novel mechanism versus standard monoaminergic drugs.\u003c\/p\u003e\n\u003cp\u003eLate-stage success could access the $140B global mental health market projected for 2026 and the $21B antidepressant market in the US (2025 est.).\u003c\/p\u003e\n\u003cp\u003eInvestors watch SPN-820 as potential blockbuster: conservative peak sales models cite $500M-$1.5B annually if approved and competitively positioned.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions of Distressed Biotech Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVolatile biotech markets in 2024-2025 left many CNS assets undervalued; Supernus Pharmaceuticals (NASDAQ: SUPN) can use its cash-about $430M in cash and equivalents at 2024 year-end-to buy late‑stage products or small firms with complementary CNS portfolios.\u003c\/p\u003e\n\u003cp\u003eAcquiring late‑stage assets could speed revenue growth and offset patent expiries on older drugs like Trokendi XR; M\u0026amp;A can plug pipeline gaps and leverage Supernus's existing sales force and infrastructure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing and Global Market Entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLicensing core products to partners in Europe and Asia could unlock sizable non-US revenue; Qelbree sales reached about $225m in 2024 in the US, so even 10% European penetration implies ~$22m annual royalties plus upfronts.\u003c\/p\u003e\n\u003cp\u003eGlobal deals would cut US-concentration risk-Supernus reported 78% of 2024 revenue from US markets-while offering immediate upfront cash (typical upfronts: $10-$100m) and multi-year royalties (5-15%).\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eQelbree 2024 US sales ~$225m\u003c\/li\u003e\n\u003cli\u003eUS = 78% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003eEstimated European 10% share ≈ $22m royalties\u003c\/li\u003e\n\u003cli\u003eUpfront ranges $10-$100m; royalties 5-15%\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreasing Diagnosis Rates in the Adult ADHD Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cprising adult adhd diagnoses-estimated us prevalence in with diagnoses up since a strong tailwind for qelbree non-stimulant approved ages that avoids stimulant side effects. supernus can capture adults seeking non-stimulants q3 net product sales growth and guidance reflected accelerating uptake. targeted digital hcp marketing penetrate this underserved fast-growing cohort.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eAdult ADHD prevalence 4.4% (2023)\u003c\/li\u003e\u003cli\u003eAdult diagnoses +30% since 2015\u003c\/li\u003e\u003cli\u003eQelbree non-stimulant-favorable safety profile\u003c\/li\u003e\u003cli\u003eQ3 2024 sales growth signaled market traction\u003c\/li\u003e\n\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline catalysts and $430M cash position set stage for global ADHD \u0026amp; Parkinson's growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSPN-830 and SPN-820 could unlock new revenue streams (SPN-830 Parkinson's device market $3.2B by 2028; SPN-820 peak sales $500M-$1.5B). Qelbree growth and rising adult ADHD (4.4% prevalence, +30% diagnoses since 2015) plus $430M cash (2024 YE) enable M\u0026amp;A, licensing (typical upfront $10-$100M; royalties 5-15%), and EU\/Asia expansion to reduce 78% US concentration.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (2024 YE)\u003c\/td\u003e\n\u003ctd\u003e$430M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQelbree US sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$225M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS revenue share (2024)\u003c\/td\u003e\n\u003ctd\u003e78%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult ADHD prevalence (2023)\u003c\/td\u003e\n\u003ctd\u003e4.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAggressive Generic Competition in the Epilepsy Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe epilepsy market is crowded with low-cost generics that undercut Supernus Pharmaceuticals' branded anticonvulsants; generic share of U.S. antiseizure prescriptions rose to ~78% in 2024, squeezing price power.\u003c\/p\u003e\n\u003cp\u003eMore entrants force deeper discounts to keep formulary placement-median insurer rebate rates climbed from ~20% in 2019 to ~38% in 2024-hitting net revenue.\u003c\/p\u003e\n\u003cp\u003eThis pricing pressure makes sustaining high growth for older anticonvulsants unlikely; Supernus saw U.S. net sales for legacy CNS products decline 12% year-over-year in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvolving Payer Landscapes and PBM Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmacy Benefit Managers and payers are pressing for higher rebates and tighter formularies, with PBM rebate demands rising ~15% industry-wide in 2024, squeezing gross margins for CNS drugs like Supernus's, which reported 2024 gross margin at ~58%. \u003c\/p\u003e\n\u003cp\u003eThese pricing pressures can limit patient access to premium therapies-メーカー placements on preferred tiers dropped 10-20% for specialty CNS agents in 2024-reducing volume and revenue upside. \u003c\/p\u003e\n\u003cp\u003eNavigating complex reimbursement rules and prior authorization hurdles remains a constant commercial challenge; delayed starts and denials can cut realized revenue by an estimated 5-12% per launch. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Rivalry within the ADHD Therapeutic Space\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe ADHD therapeutic space is crowded: global ADHD drug sales reached about $16.5B in 2024, dominated by legacy stimulants and newer non-stimulant launches from Pfizer, Vertex, and Johnson \u0026amp; Johnson, increasing pricing pressure on Supernus Pharmaceuticals. Rivals often outspend Supernus on marketing-top firms report ad and promotion budgets \u0026gt;$500M annually-shaping prescribing habits and payer contracts. To hold share, Supernus must continuously innovate and deliver clear clinical differentiation through costly trials and real-world evidence programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential Legislative Changes to Prescription Drug Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePotential federal laws expanding Medicare drug-price negotiation and proposals like H.R. 3-style frameworks could cut branded drug revenues; estimates suggest negotiated discounts of 20-40% could apply to high-spend CNS drugs, hitting Supernus Pharmaceuticals' core products.\u003c\/p\u003e\n\u003cp\u003ePrivate payer shifts toward value-based pricing for CNS (central nervous system) therapies may lower net realized prices; average net price erosion of 10-15% was seen in similar classes in 2023-2024.\u003c\/p\u003e\n\u003cp\u003eRegulatory uncertainty complicates long-term forecasting and valuation; a 25% price shock reduces steady-state free cash flow and could lower enterprise value by roughly 15-30% depending on discount rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare negotiation risk: 20-40% cuts\u003c\/li\u003e\n\u003cli\u003ePrivate payer erosion: 10-15% net price decline\u003c\/li\u003e\n\u003cli\u003eValuation impact: ~15-30% EV downside on 25% shock\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRisk of Clinical Trial Failures for Early-Stage Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe high failure rate for central nervous system (CNS) drugs-only ~8-10% phase I-to-approval success versus ~13% overall in 2020-2024-threatens Supernus' early-stage pipeline value, making SPN-820 and other candidates vulnerable to trial setbacks.\u003c\/p\u003e\n\u003cp\u003eNegative data from SPN-820 or parallel programs would likely trigger multi‑million to potentially \u0026gt;$100m write‑downs and a sharp share reprice given Supernus' market cap was about $1.1bn in late 2025.\u003c\/p\u003e\n\u003cp\u003eBrain disorders' biological complexity raises technical risk, longer timelines, and higher R\u0026amp;D burn rates, increasing the chance investor confidence falls after adverse readouts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8-10% CNS success rate\u003c\/li\u003e\n\u003cli\u003e~$1.1bn market cap (late 2025)\u003c\/li\u003e\n\u003cli\u003ePotential \u0026gt;$100m write‑downs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupernus faces margin squeeze and high clinical risk-$100M+ write‑down and 20-40% price cuts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePricing headwinds from generics and PBM rebate escalation trimmed Supernus' 2024 gross margin to ~58% and cut legacy CNS sales 12% YoY; payer shifts and Medicare negotiation risk (20-40% cuts) threaten further net-price erosion of 10-15% seen industry-wide. Clinical risk is high: CNS phase I‑to‑approval ~8-10%, making SPN‑820 setbacks capable of \u0026gt;$100m write‑downs and sharp market‑cap repricing (SPN market cap ~ $1.1bn late 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric\/payer pressure\u003c\/td\u003e\n\u003ctd\u003e78% generic share (2024); gross margin ~58%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRebates\/formulary\u003c\/td\u003e\n\u003ctd\u003eMedian rebate ~38% (2024); insurer demands +15% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation\u003c\/td\u003e\n\u003ctd\u003e20-40% potential cuts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline risk\u003c\/td\u003e\n\u003ctd\u003e8-10% approval rate; \u0026gt;$100m write‑down risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53678644855126,"sku":"supernus-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/supernus-swot-analysis.webp?v=1778899672","url":"https:\/\/balancedscorecardexamples.com\/products\/supernus-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}